期刊文献+

腹膜透析相关性腹膜炎患者易感病原菌及耐药性分析 被引量:7

Frequent Species and resistance of pathogens causing infections in Patients with peritoneal dialysis related peritonitis in our hospital from 2013 to 2014
下载PDF
导出
摘要 目的探讨腹膜透析相关性腹膜炎(PDAP)患者的致病菌分布和药敏特点,为临床合理利用抗菌药物提供依据。方法采取回顾性方法分析2013年1月-2014年12月就诊的PDAP患者的致病菌分布及耐药性。结果423例PDAP患者,其中195例培养阳性,培养阳性率为46.1%,共检出致病菌198株。其中革兰阳性菌119株(60.1%),革兰阴性菌中肠杆菌属35株(17.7%),真菌40株(20.2%)。葡萄球菌属对的耐药率替考拉宁最低,为3.3%;对青霉素耐药率最高为96.7%。肠杆菌属对阿米卡星和美罗培南均有较高敏感性。结论 PDAD的致病菌以革兰阳性菌为主,且对临床抗菌药物呈现出不同的耐药性。在经验用药基础上,应依据病原菌培养、药敏结果,选择治疗PDAP的合适抗生素。 Objective To investigate the distribution and drug resistance of pathogenic bacteria of peritonitis in peri- toneal dialysis-associated peritonitis (PDAP) ,in order to provide basis for the reasonable use of antibiotics. Methods Perito- neal dialysis-related peritonitis, who were treated in the hospital from Jan 2013 to Dec 2014 ,were collected in the study, then the distribution and drug resistance of the pathogens were retrospectively analyzed. Results ( 1 ) Among 423 cases of PDAP patients with peritonitis, 195 cases were tested positive for pathogenic bacteria, with positive rate of 46.1%. There were culti- vated 198 strains,including Gram-positive bacteria ( 119 strains, 60. 1% ), Gram-negative bacteria (35 strains, 17.7% ) and fungus (40 strains,20.2% ). (2) Staphylococcus showed lowest resistance to Teicoplanin (3.3%), and highest resistance to Penicillin (96.7%). (3) Enterobacter kept good sensitivity to Amikacin and Meropenemforlnjection. Conclusion Gram-pos- itive bacteria are the most common pathogens of peritonitis in patients undergoing PDAP, and shows different degree of resist- ance to common clinical antibiotics. In the empirical treatment, we should be on the basis of the pathogenic bacteria culture and drug susceptibility results, effective treatment for peritoneal dialysis related peritonitis sensitive antibiotics.
出处 《临床合理用药杂志》 2015年第26期25-26,共2页 Chinese Journal of Clinical Rational Drug Use
基金 广东省医学科研基金项目(A2013622) 广东省大学生创新训练项目(1057112047) 湛江市非资助科技攻关计划项目(2012C3104014)
关键词 腹膜透析相关性腹膜炎 病原菌 耐药性 Peritoneal dialysis related peritonitis Pathogen Drug resistance
  • 相关文献

参考文献8

  • 1Lafrance JP, Rahme E, Iqbal S, et al. Association of dialysis modality with risk for infection-related hospitalization:a propensity score-matched cohort analysis [ J ]. Clin J Am Soc Nephrol,2012,7 (10) :1598 - 1605.
  • 2Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations :2010 update [ J ]. Petit Dial Int, 2010,30 (4) : 393 - 423.
  • 3Basturk T, Koc Y, Unsal A, et al. Fungal peritonitis in peritoneal dialy- sis:a 10 year retrospective analysis in a single center [J ]. Eur Rev Med Pharmacol Sci ,2012,16 ( 12 ), 1696 - 1700.
  • 4van Esch S, Krediet RT,Struijk DG. Prognostic factors for peritonitis out- come [ J ]. Contrib Nephro1,2012 ,178 ,264 - 270.
  • 5郭群英,陈林,阳晓,杨念生,冯敏,姜宗培,毛海萍,陈崴,余学清.腹膜透析相关感染性腹膜炎致病菌及菌谱变化——单个腹膜透析中心15年回顾分析[J].中华肾脏病杂志,2006,22(12):719-724. 被引量:64
  • 6Govindarajulu S, Hawley CM, McDonald SP, et al. Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients:predictors, treatment and outcomes in 503 case[J ]. Perit Dial Int,2010,30(3 ) :311 -319.
  • 7吴晶晶,刘佳,张莉,王珏,邢昌赢.腹膜透析相关性腹膜炎致病菌及耐药性分析[J].中华医院感染学杂志,2011,21(16):3521-3523. 被引量:22
  • 8Huang ST, Chuang YW, Cheng CH, et al. Evolution of microbiological trends and treatment outcomes in peritoneal dialysis-related peritonitis [J ]. Clin Nephrol,2011,75 (5) :416 -425.

二级参考文献30

  • 1Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations:2010 update[J]. Petit Dial Int, 2010,30(4) : 393-423.
  • 2Yoon SH,Choi NW,Yun SR. Detecting bacterial growth in con- tiruous ambulatory peritoneal dialysis effluent using two culture methods[J]. Korean J Intern Med,2010,25(1) :82-85.
  • 3Shigidi MM, Fituri OM, Chandy SK, et al. Microbial spec- trum and outcome of peritoneal dialysis related peritonitis in Qatar[J]. Saudi J Kidney Dis Transpl, 2010,21 (1) : 168-173.
  • 4Strippoli GF,Tong A,Johnson D,et al. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients [J]. Cochrane Database Syst Rev, 2004,18 (4) :CD004679.
  • 5Lui SL, Cheng SW, Ng SY, et al. Cefazolin plus netilmicin versus cefazolin plus eeftazidime for treating CAPD peritonitis: effect on residual renal function[J]. Kidney Int,2005,68(5) :2375-2380.
  • 6Keane WF, Bailie GR, Boesehoten E, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Petit Dial Int, 2000, 20:396-411.
  • 7Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysisrelated infections recommendations: 2005 update. Petit Dial Int, 2005, 25:107-131.
  • 8Saito T, Iinuma Y, Takakura S, et al. Can BacT/Alert FA and FN blood culture bottles increase the recovery of microorganisms in the clinical laboratory? J Infect Chemother,2004, 10:343-347.
  • 9Zelenitsky S, Barns L, Findlay I, et al. Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis, 2000, 36: 1009-1013.
  • 10Korbet SM, Vonesh EF, Firanek CA. Peritonitis in an urban peritoneal dialysis program: an analysis of infecting pathogens.Am J Kidney Dis, 1995, 26:47-53.

共引文献80

同被引文献27

引证文献7

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部